May 2024

– Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial – Long-term efficacy r

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: